A Phase 2 interventional study of QLS-101ophthalmic solution 1% and QLS-101ophthalmic solution 2% in Sturge-Weber Syndrome (SWS), Glaucoma and Glaucoma Congenital, sponsored by Qlaris Bio, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.
Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment
Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 95 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 351st largest by enrollment of the 364 interventional ones that give a count, is one of 21 that started in 2021, is one of 66 in phase 2, and was the 361st registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Tavo Biotherapeutics · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 357 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
Qlaris Bio, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Qlaris Bio, Inc. has 8 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101. Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of daily dosing, and after a 14-day washout period they will be crossed over to the other concentration for another 14 days of daily dosing. Dose assignment is masked to patient and investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dosed once a day for 14 days as either first or second dosing period per randomization
Drug: QLS-101ophthalmic solution 1%
dosed once a day for 14 as either first or second dosing period per randomization
Drug: QLS-101ophthalmic solution 2%
QLS-101ophthalmic solution 1.0%
Also known as: QLS-101
QLS-101ophthalmic solution 2.0%
Also known as: QLS-101
Ocular adverse events (AEs)
Standard safety endpoint, ocular AEs, (including elevated IOP)
Time frame: 56 days, including a 14-day washout
Visual acuity
Standard safety endpoint, best corrected visual acuity, Snellen score, change from baseline
Time frame: 56 days, including a 14-day washout
Enhance depth imaging optical coherence tomography (EDI-OCT)
Standard safety endpoint, EDI-OCT, corneal thickness
Time frame: 56 days, including a 14-day washout
Slit lamp exam
Standard safety endpoint, slit lamp exam, abnormalities, changes from baseline
Time frame: 56 days, including a 14-day washout
Dilated fundus exam
Fundus exam, abnormalities, changes from baseline
Time frame: 56 days, including a 14-day washout
Ocular hypotensive efficacy
Mean change in IOP from baseline following 14 days dosing
Time frame: 14 days after each dosing timepoint is completed
Plan to share: No
Ran from Oct 2021 to primary completion in Jun 2022, 7 months.
Of 23 industry-sponsored phase 2 interventional studies under Glaucoma, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 11. This study's 7 months is close to that.
Counting every sponsor, half of 32 studies reached it within 11 months; a quarter within 6 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Foslevcromakalim
Qlaris Bio, Inc.